Pathophysiology of traumatic brain injury

Neurosciences

Volumn 18, Issue 3, 2013, Pages 222-234

  Mustafa, Ayman G ^a   Al Shboul, Othaman A ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AK 295; CALCIUM ION; CALPAIN; CALPASTATIN; GLUTAMIC ACID; N (4 FLUOROPHENYLSULFONYL)VALYLLEUCINAL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXYGEN RADICAL; PEROXYNITRITE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SPECTRIN; UNCLASSIFIED DRUG; [1 [(1 BENZYL 3 CYCLOPROPYLAMINO 2,3 DIOXOPROPYL)CARBAMOYL] 3 METHYLBUTYL]CARBAMIC ACID 2 (2 METHOXYETHOXY)ETHYL ESTER;

AMINO ACID TRANSPORT; AXONAL INJURY; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN METABOLISM; BRAIN VASCULAR RESISTANCE; BRAIN VASOSPASM; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CEREBRAL PERFUSION PRESSURE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPIDURAL HEMATOMA; EXCITOTOXICITY; HEMODYNAMICS; HUMAN; INJURY SEVERITY; INTRACRANIAL PRESSURE; LIPID PEROXIDATION; MEAN ARTERIAL PRESSURE; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NERVOUS SYSTEM PARAMETERS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; RESPIRATORY CHAIN; REVIEW; SUBDURAL HEMATOMA; TRAUMATIC BRAIN INJURY;

EID: 84911471215     PISSN: 13196138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Finfer SR, Cohen J. Severe traumatic brain injury. Resuscitation 2001; 48: 77-90.
2. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007; 99: 4-9.
3. Marik PE, Varon J, Trask T. Management of head trauma. Chest 2002; 122: 699-711.
4. Riggio S, Wong M. Neurobehavioral sequelae of traumatic brain injury. Mt Sinai J Med 2009; 76: 163-172.
5. Madikians A. A Clinician's Guide to the Pathophysiology of Traumatic Brain Injury. Indian Journal of Neurotrauma 2006; 3: 9-17.
6. Bayir H, Marion DW, Puccio AM, Wisniewski SR, Janesko KL, Clark RS, et al. Marked gender efect on lipid peroxidation after severe traumatic brain injury in adult patients. J Neurotrauma 2004; 21: 1-8.
7. Roof RL, Hall ED. Estrogen-related gender diference in survival rate and cortical blood fow after impact-acceleration head injury in rats. J Neurotrauma 2000; 17: 1155-1169.
8. Smith-Seemiller L, Lovell MR, Smith S, Markosian N, Townsend RN. Impact of skull fracture on neuropsychological functioning following closed head injury. Brain Inj 1997; 11: 191-196.
9. Gerlach R, Dittrich S, Schneider W, Ackermann H, Seifert V, Kieslich M. Traumatic epidural hematomas in children and adolescents: outcome analysis in 39 consecutive unselected cases. Pediatr Emerg Care 2009; 25: 164-169.
10. Senft C, Schuster T, Forster MT, Seifert V, Gerlach R. Management and outcome of patients with acute traumatic subdural hematomas and pre-injury oral anticoagulation therapy. Neurol Res 2009; 31: 1012-1018.
11. Smith DH, Meaney D F, Shull WH. Difuse axonal injury in head trauma. J Head Trauma Rehabil 2003; 18: 307-316.
12. Chung SW, Park YS, Nam TK, Kwon JT, Min BK, Hwang SN. Locations and clinical signifcance of non-hemorrhagic brain lesions in difuse axonal injuries. J Korean Neurosurg Soc 2012; 52: 377-383.
13. Buki A, Povlishock JT. All roads lead to disconnection?--Traumatic axonal injury revisited. Acta Neurochir (Wien) 2006; 148: 181-194.
14. Park E, Bell JD, Baker AJ. Traumatic brain injury: can the consequences be stopped? CMAJ 2008; 178: 1163-1170.
15. Greve MW, Zink BJ. Pathophysiology of traumatic brain injury. Mt Sinai J Med 2009; 76: 97-104.
16. Graham DI, Ford I, Adams JH, Doyle D, Teasdale GM, Lawrence AE, et al. Ischaemic brain damage is still common in fatal non-missile head injury. J Neurol Neurosurg Psychiatry 1989; 52: 346-350.
17. Marion DW, Darby J, Yonas H. Acute regional cerebral blood fow changes caused by severe head injuries. J Neurosurg 1991; 74: 407-414.
18. McLaughlin MR, Marion DW. Cerebral blood fow and vasoresponsivity within and around cerebral contusions. J Neurosurg 1996; 85: 871-876.
19. Salvant JB Jr, Muizelaar J P. Changes in cerebral blood fow and metabolism related to the presence of subdural hematoma. Neurosurgery 1993; 33: 387-393.
20. Botteri M, Bandera E, Minelli C, Latronico N. Cerebral blood fow thresholds for cerebral ischemia in traumatic brain injury. A systematic review. Crit Care Med 2008; 36: 3089-3092.
21. White H, Venkatesh B. Cerebral perfusion pressure in neurotrauma: a review. Anesth Analg 2008; 107: 979-988.
22. Gupta AK. Monitoring the injured brain in the intensive care unit. J Postgrad Med 2002; 48: 218-225.
23. O'Phelan KH, Park D, Efrd JT, Johnson K, Albano M, Beniga J, et al. Patterns of increased intracranial pressure after severe traumatic brain injury. Neurocrit Care 2009; 10: 280-286.
24. Johnston IH, Johnston JA, Jennett B. Intracranial-pressure changes following head injury. Lancet 1970; 2: 433-436.
25. Czigner A, Mihaly A, Farkas O, Buki A, Krisztin-Peva B, Dobo E, et al. Kinetics of the cellular immune response following closed head injury. Acta Neurochir (Wien) 2007; 149: 281-289.
26. Dostal P, Cerny V, Parizkova R. Sepsis: cause of late deterioration of intracranial pressure in patients with severe traumatic brain injury? Crit Care 1998; 2 (Supp 1): P061.
27. Kelly BJ, Luce JM. Current concepts in cerebral protection. Chest 1993; 103: 1246-1254.
28. Jones SC, Radinsky CR, Furlan AJ, Chyatte D, Perez-Trepichio AD. Cortical NOS inhibition raises the lower limit of cerebral blood fow-arterial pressure autoregulation. Am J Physiol 1999; 276: H1253-H1262.
29. Morillo CA, Ellenbogen KA, Fernando Pava L. Pathophysiologic basis for vasodepressor syncope. Cardiol Clin 1997; 15: 233-249.
30. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013; 698: 6-18.
31. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008; 7: 728-741.
32. Zipfel GJ, Babcock DJ, Lee JM, Choi DW. Neuronal apoptosis after CNS injury: the roles of glutamate and calcium. J Neurotrauma 2000; 17: 857-869.
33. Lynch DR, Dawson TM. Secondary mechanisms in neuronal trauma. Curr Opin Neurol 1994; 7: 510-516.
34. Hayes RL, Jenkins LW, Lyeth BG. Neurotransmitter-mediated mechanisms of traumatic brain injury: acetylcholine and excitatory amino acids. J Neurotrauma 1992; 9 Suppl 1: S173-S187.
35. Faden AI, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989; 244: 798-800.
36. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15: 961-973.
37. Tymianski M, Tator CH. Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Neurosurgery 1996; 38: 1176-1195.
38. Deng Y, Tompson BM, Gao X, Hall ED. Temporal relationship of peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury. Exp Neurol 2007; 205: 154-165.
39. Choi D W. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987; 7: 369-379.
40. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett 1985; 58: 293-297.
41. Bullock R, Zauner A, Myseros JS, Marmarou A, Woodward JJ, Young H F. Evidence for prolonged release of excitatory amino acids in severe human head trauma. Relationship to clinical events. Ann N Y Acad Sci 1995; 765: 290-298.
42. Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int 2006; 48: 394-403.
43. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105.
44. Berger UV, Hediger MA. Comparative analysis of glutamate transporter expression in rat brain using diferential double in situ hybridization. Anat Embryol (Berl) 1998; 198: 13-30.
45. Kugler P, Schmitt A. Glutamate transporter EAAC1 is expressed in neurons and glial cells in the rat nervous system. Glia 1999; 27: 129-142.
46. Kondratskaya E, Shin MC, Akaike N. Neuronal glutamate transporters regulate synaptic transmission in single synapses on CA1 hippocampal neurons. Brain Res Bull 2010; 81: 53-60.
47. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997; 276: 1699-1702.
48. Peghini P, Janzen J, Stofel W. Glutamate transporter EAAC-1-defcient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. Embo J 1997; 16: 3822-3832.
49. Chaudhry FA, Lehre K P, van Lookeren Campagne M, Ottersen O P, Danbolt NC, Storm-Mathisen J. Glutamate transporters in glial plasma membranes: highly diferentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 1995; 15: 711-720.
50. Rao VL, Baskaya MK, Dogan A, Rothstein JD, Dempsey RJ. Traumatic brain injury down-regulates glial glutamate transporter (GLT-1 and GLAST) proteins in rat brain. J Neurochem 1998; 70: 2020-2027.
51. van Landeghem FK, Weiss T, Oehmichen M, von Deimling A. Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma 2006; 23: 1518-1528.
52. van Landeghem FK, Stover J F, Bechmann I, Bruck W, Unterberg A, Buhrer C, et al. Early expression of glutamate transporter proteins in ramifed microglia after controlled cortical impact injury in the rat. Glia 2001; 35: 167-179.
53. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989; 29: 365-402.
54. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. 7th ed. New York (NY): Oxford University Press; 1996.
55. Bettler B, Mulle C. Review: neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology 1995; 34: 123-139.
56. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001; 11: 327-335.
57. Mark L P, Prost RW, Ulmer JL, Smith MM, Daniels DL, Strottmann JM, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. AJNR Am J Neuroradiol 2001; 22: 1813-1824.
58. Tymianski M, Charlton M P, Carlen PL, Tator CH. Source specifcity of early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 1993; 13: 2085-2104.
59. Randall RD, Tayer SA. Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons. J Neurosci 1992; 12: 1882-1895.
60. Rajdev S, Reynolds IJ. Glutamate-induced intracellular calcium changes and neurotoxicity in cortical neurons in vitro: efect of chemical ischemia. Neuroscience 1994; 62: 667-679.
61. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003; 34: 325-337.
62. Swanson CJ, Bures M, Johnson M P, Linden AM, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005; 4: 131-144.
63. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010; 50: 295-322.
64. Chen T, Willoughby KA, Ellis EF. Group I metabotropic receptor antagonism blocks depletion of calcium stores and reduces potentiated capacitative calcium entry in strain-injured neurons and astrocytes. J Neurotrauma 2004; 21: 271-281.
65. Lea PM 4th, Faden AI. Traumatic brain injury: developmental diferences in glutamate receptor response and the impact on treatment. Ment Retard Dev Disabil Res Rev 2001; 7: 235-248.
66. Gegelashvili G, Dehnes Y, Danbolt NC, Schousboe A. The high-afnity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via diferent signalling mechanisms. Neurochem Int 2000; 37: 163-170.
67. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 4th ed. New York: Oxford University Press Inc; 2007.
68. Kontos HA, Povlishock J T. Oxygen radicals in brain injury. Cent Nerv Syst Trauma 1986; 3: 257-263.
69. Kontos HA, Wei E P. Superoxide production in experimental brain injury. J Neurosurg 1986; 64: 803-807.
70. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000; 17: 871-890.
71. Chaudière J, Ferrari-Iliou R. Intracellular antioxidants: from chemical to biochemical mechanisms. Food Chem Toxicol 1999; 37: 949-962.
72. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41 (12 Pt 2): 1819-1828.
73. Zaleska MM, Floyd RA. Regional lipid peroxidation in rat brain in vitro: possible role of endogenous iron. Neurochem Res 1985; 10: 397-410.
74. Rehncrona S, Hauge HN, Siesjo BK. Enhancement of iron-catalyzed free radical formation by acidosis in brain homogenates: diferences in efect by lactic acid and CO2. J Cereb Blood Flow Metab 1989; 9: 65-70.
75. Hall ED, Vaishnav RA, Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics 2010; 7: 51-61.
76. Sadrzadeh SM, Eaton JW. Hemoglobin-mediated oxidant damage to the central nervous system requires endogenous ascorbate. J Clin Invest 1988; 82: 1510-1515.
77. Sadrzadeh SM, Graf E, Panter SS, Hallaway PE, Eaton JW. Hemoglobin. A biologic fenton reagent. J Biol Chem 1984; 259: 14354-14356.
78. Hall ED, McCall JM, Means ED. Terapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol 1994; 28: 221-268.
79. Hall ED, Braughler JM. Free radicals in CNS injury. Res Publ Assoc Res Nerv Ment Dis 993; 71: 81-105.
80. Smith SL, Andrus PK, Zhang JR, Hall ED. Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat. J Neurotrauma 1994; 11: 393-404.
81. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271 (5 Pt 1): C1424-C1437.
82. Alvarez MN, Trujillo M, Radi R. Peroxynitrite formation from biochemical and cellular fuxes of nitric oxide and superoxide. Methods Enzymol 2002; 359: 353-366.
83. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991; 288: 481-487.
84. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003; 25: 295-311.
85. Bartesaghi S, Ferrer-Sueta G, Pelufo G, Valez V, Zhang H, Kalyanaraman B, et al. Protein tyrosine nitration in hydrophilic and hydrophobic environments. Amino Acids 2007; 32: 501-515.
86. Cobbs CS, Fenoy A, Bredt DS, Noble LJ. Expression of nitric oxide synthase in the cerebral microvasculature after traumatic brain injury in the rat. Brain Res 1997; 751: 336-338.
87. Rao VL, Dogan A, Bowen KK, Dempsey RJ. Traumatic injury to rat brain upregulates neuronal nitric oxide synthase expression and L-[3H]nitroarginine binding. J Neurotrauma 1999; 16: 865-877.
88. Gahm C, Holmin S, Mathiesen T. Temporal profles and cellular sources of three nitric oxide synthase isoforms in the brain after experimental contusion. Neurosurgery 2000; 46: 169-177.
89. Mésenge C, Charriaut-Marlangue C, Verrecchia C, Allix M, Boulu RR, Plotkine M. Reduction of tyrosine nitration after N(omega)-nitro-L-arginine-methylester treatment of mice with traumatic brain injury. Eur J Pharmacol 1998; 353: 53-57.
90. Mésenge C, Margaill I, Verrecchia C, Allix M, Boulu RG, Plotkine M. Protective efect of melatonin in a model of traumatic brain injury in mice. J Pineal Res 1998; 25: 41-46.
91. Radi R, Cassina A, Hodara R, Quijano C, Castro L. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002; 33: 1451-1464.
92. Deng-Bryant Y, Singh IN, Carrico KM, Hall ED. Neuroprotective efects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model. J Cereb Blood Flow Metab 2008; 28: 1114-1126.
93. Kasprzak HA, Woźniak A, Drewa G, Woźniak B. Enhanced lipid peroxidation processes in patients after brain contusion. J Neurotrauma 2001; 18: 793-797.
94. Zhang D, Dhillon HS, Mattson MP, Yurek DM, Prasad RM. Immunohistochemical detection of the lipid peroxidation product 4-hydroxynonenal after experimental brain injury in the rat. Neurosci Lett 1999; 272: 57-61.
95. Falletti O, Cadet J, Favier A, Douki T. Trapping of 4-hydroxynonenal by glutathione efciently prevents formation of DNA adducts in human cells. Free Radic Biol Med 2007; 42: 1258-1269.
96. Keller JN, Mark RJ, Bruce AJ, Blanc E, Rothstein JD, Uchida K, et al. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 1997; 80: 685-696.
97. Pedersen WA, Cashman NR, Mattson M P. The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp Neurol 1999; 155: 1-10.
98. Durmaz R, Kanbak G, Akyüz F, Isiksoy S, Yücel F, Inal M, et al. Lazaroid attenuates edema by stabilizing ATPase in the traumatized rat brain. Can J Neurol Sci 2003; 30: 143-149.
99. Racay P, Kaplán P, Mézesová V, Lehotský J. Lipid peroxidation both inhibits Ca(2+)-ATPase and increases Ca2+ permeability of endoplasmic reticulum membrane. Biochem Mol Biol Int 1997; 41: 647-655.
100. Mustafa AG, Singh IN, Wang J, Carrico KM, Hall ED. Mitochondrial protection after traumatic brain injury by scavenging lipid peroxyl radicals. J Neurochem 2010; 114: 271-280.
101. Singh IN, Gilmer LK, Miller DM, Cebak JE, Wang JA, Hall ED. Phenelzine mitochondrial functional preservation and neuroprotection after traumatic brain injury related to scavenging of the lipid peroxidation-derived aldehyde 4-hydroxy-2-nonenal. J Cereb Blood Flow Metab 2013; 33: 593-599.
102. Singh IN, Sullivan PG, Deng Y, Mbye LH, Hall ED. Time course of mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J Cereb Blood Flow Metab 2006; 26: 1407-1418.
103. Gunter TE, Yule DI, Gunter KK, Eliseev RA, Salter JD. Calcium and mitochondria. FEBS Lett 2004; 567: 96-102.
104. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 2005; 70: 363-374.
105. Kann O, Kovács R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007; 292: C641-C657.
106. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 2000; 80: 315-360.
107. Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, et al. Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta 2009; 1787: 335-344.
108. Lifshitz J, Sullivan PG, Hovda DA, Wieloch T, McIntosh TK. Mitochondrial damage and dysfunction in traumatic brain injury. Mitochondrion 2004; 4: 705-713.
109. Mbye LH, Singh IN, Sullivan PG, Springer JE, Hall ED. Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog. Exp Neurol 2008; 209: 243-253.
110. Opii WO, Nukala VN, Sultana R, Pandya JD, Day KM, Merchant ML, et al. Proteomic identifcation of oxidized mitochondrial proteins following experimental traumatic brain injury. J Neurotrauma 2007; 24: 772-789.
111. Verweij BH, Muizelaar J P, Vinas FC, Peterson PL, Xiong Y, Lee C P. Impaired cerebral mitochondrial function after traumatic brain injury in humans. J Neurosurg 2000; 93: 815-820.
112. Buczek M, Alvarez J, Azhar J, Zhou Y, Lust WD, Selman WR, et al. Delayed changes in regional brain energy metabolism following cerebral concussion in rats. Metab Brain Dis 2002; 17: 153-167.
113. Mautes AE, Tome D, Steudel WI, Nacimiento AC, Yang Y, Shohami E. Changes in regional energy metabolism after closed head injury in the rat. J Mol Neurosci 2001; 16: 33-39.
114. Lee SM, Wong MD, Samii A, Hovda DA. Evidence for energy failure following irreversible traumatic brain injury. Ann N Y Acad Sci 1999; 893: 337-340.
115. Albensi BC, Sullivan PG, Tompson MB, Schef SW, Mattson M P. Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity. Exp Neurol 2000; 162: 385-389.
116. Verweij BH, Muizelaar J P, Vinas FC, Peterson PL, Xiong Y, Lee C P. Mitochondrial dysfunction after experimental and human brain injury and its possible reversal with a selective N-type calcium channel antagonist (SNX-111). Neurol Res 1997; 19: 334-339.
117. Sullivan PG, Keller JN, Mattson M P, Schef SW. Traumatic brain injury alters synaptic homeostasis: implications for impaired mitochondrial and transport function. J Neurotrauma 1998; 15: 789-798.
118. Sullivan PG, Tompson MB, Schef SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol 1999; 160: 226-234.
119. Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996; 67: 2282-2291.
120. Nicholls DG, Ward MW. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivo. Trends Neurosci 2000: 23: 166-174.
121. Xiong Y, Gu Q, Peterson PL, Muizelaar J P, Lee C P. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma 1997; 14: 23-34.
122. Xiong Y, Peterson PL, Muizelaar J P, Lee C P. Amelioration of mitochondrial function by a novel antioxidant U-101033E following traumatic brain injury in rats. J Neurotrauma 1997; 14: 907-917.
123. Brustovetsky N, Brustovetsky T, Jemmerson R, Dubinsky JM. Calcium-induced cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane. J Neurochem 2002; 80: 207-218.
124. Lifshitz J, Friberg H, Neumar RW, Raghupathi R, Welsh FA, Janmey P, et al. Structural and functional damage sustained by mitochondria after traumatic brain injury in the rat: evidence for diferentially sensitive populations in the cortex and hippocampus. J Cereb Blood Flow Metab 2003; 23: 219-231.
125. Hansson MJ, Månsson R, Morota S, Uchino H, Kallur T, Sumi T, et al. Calcium-induced generation of reactive oxygen species in brain mitochondria is mediated by permeability transition. Free Radic Biol Med 2008; 45: 284-294.
126. Gadelha FR, Tomson L, Fagian MM, Costa AD, Radi R, Vercesi AE. Ca2+-independent permeabilization of the inner mitochondrial membrane by peroxynitrite is mediated by membrane protein thiol cross-linking and lipid peroxidation. Arch Biochem Biophys 1997; 345: 243-250.
127. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26: 463-471.
128. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or efect of neuronal cell death? J Neurosci Res 2005; 79: 231-239.
129. Jacquard C, Trioulier Y, Cosker F, Escartin C, Bizat N, Hantraye P, et al. Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB J 2006; 20: 1021-1023.
130. Robertson CL. Mitochondrial dysfunction contributes to cell death following traumatic brain injury in adult and immature animals. J Bioenerg Biomembr 2004; 36: 363-368.
131. Lewen A, Fujimura M, Sugawara T, Matz P, Copin JC, Chan PH. Oxidative stress-dependent release of mitochondrial cytochrome c after traumatic brain injury. J Cereb Blood Flow Metab 2001; 21: 914-920.
132. Sullivan PG, Tompson M, Schef SW. Continuous infusion of cyclosporin A postinjury signifcantly ameliorates cortical damage following traumatic brain injury. Exp Neurol 2000; 161: 631-637.
133. Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective efects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab 2009; 29: 87-97.
134. Sullivan PG, Sebastian AH, Hall ED. Terapeutic window analysis of the neuroprotective efects of cyclosporine A after traumatic brain injury. J Neurotrauma 2011; 28: 311-318.
135. Suzuki K, Hata S, Kawabata Y, Sorimachi H. Structure, activation, and biology of calpain. Diabetes 2004; 53 Suppl 1: S12-S18.
136. Huang Y, Wang KK. The calpain family and human disease. Trends Mol Med 2001; 7: 355-362.
137. Goll DE, Tompson V F, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003; 83: 731-801.
138. Wu HY, Lynch DR. Calpain and synaptic function. Mol Neurobiol 2006; 33: 215-236.
139. Fineman I, Hovda DA, Smith M, Yoshino A, Becker D P. Concussive brain injury is associated with a prolonged accumulation of calcium: a 45Ca autoradiographic study. Brain Res 1993; 624: 94-102.
140. Nilsson P, Laursen H, Hillered L, Hansen AJ. Calcium movements in traumatic brain injury: the role of glutamate receptor-operated ion channels. J Cereb Blood Flow Metab 1996; 16: 262-270.
141. Saatman KE, Creed J, Raghupathi R. Calpain as a therapeutic target in traumatic brain injury. Neurotherapeutics 2010; 7: 31-42.
142. Goodman SR, Zimmer WE, Clark MB, Zagon IS, Barker JE, Bloom ML. Brain spectrin: of mice and men. Brain Res Bull 1995; 36: 593-606.
143. Harris AS, Morrow JS. Proteolytic processing of human brain alpha spectrin (fodrin): identifcation of a hypersensitive site. J Neurosci 1988; 8: 2640-2651.
144. Pineda JA, Wang KK, Hayes RL. Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol 2004; 14: 202-209.
145. Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL. Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fuid after traumatic brain injury in rats. J Neurochem 2001; 78: 1297-1306.
146. Bartus RT, Elliott PJ, Hayward NJ, Dean RL, Harbeson S, Straub JA, et al. Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res 1995; 17: 249-258.
147. Saatman KE, Bozyczko-Coyne D, Marcy V, Siman R, McIntosh TK. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol 1996; 55: 850-860.
148. Kampf A, Posmantur R, Nixon R, Grynspan F, Zhao X, Liu SJ, et al. Mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J Neurochem 1996; 67: 1575-1583.
149. Büki A, Siman R, Trojanowski JQ, Povlishock JT. The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury. J Neuropathol Exp Neurol 1999; 58: 365-375.
150. Pineda JA, Lewis SB, Valadka AB, Papa L, Hannay HJ, Heaton SC, et al. Clinical signifcance of alphaII-spectrin breakdown products in cerebrospinal fuid after severe traumatic brain injury. J Neurotrauma 2007; 24: 354-366.
151. Brophy GM, Pineda JA, Papa L, Lewis SB, Valadka AB, Hannay HJ, et al. AlphaII-Spectrin breakdown product cerebrospinal fuid exposure metrics suggest diferences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma 2009; 26: 471-479.
152. Posmantur R, Kampf A, Siman R, Liu J, Zhao X, Clifton GL, et al. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience 1997; 77: 875-888.
153. Bains M, Cebak JE, Gilmer LK, Barnes CC, Tompson SN, Geddes JW, et al. Pharmacological analysis of the cortical neuronal cytoskeletal protective efcacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model. J Neurochem 2013; 125: 125-132.
154. Saatman KE, Murai H, Bartus RT, Smith DH, Hayward NJ, Perri BR, et al. Calpain inhibitor AK295 attenuates motor and cognitive defcits following experimental brain injury in the rat. Proc Natl Acad Sci U S A 1996; 93: 3428-3433.
155. Kupina NC, Nath R, Bernath EE, Inoue J, Mitsuyoshi A, Yuen PW, et al. The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of difuse brain injury. J Neurotrauma 2001; 18: 1229-1240.